scispace - formally typeset
Journal ArticleDOI

Interpreting the significance of changes in health-related quality-of-life scores.

David Osoba, +4 more
- 01 Jan 1998 - 
- Vol. 16, Iss: 1, pp 139-144
Reads0
Chats0
TLDR
The significance of changes in QLQ-C30 scores can be interpreted in terms of small, moderate, or large changes in quality of life as reported by patients in the SSQ.
Abstract: 
PURPOSETo determine the significance to patients of changes in health-related quality-of-life (HLQ) scores assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30).PATIENTS AND METHODSA subjective significance questionnaire (SSQ), which asks patients about perceived changes in physical, emotional, and social functioning and in global quality of life (global QL) and the QLQ-C30 were completed by patients who received chemotherapy for either breast cancer or small-cell lung cancer (SCLC). In the SSQ, patients rated their perception of change since the last time they completed the QLQ-C30 using a 7-category scale that ranged from "much worse" through "no change" to "much better." For each category of change in the SSQ, the corresponding differences were calculated in QLQ-C30 mean scores and effect sizes were determined.RESULTSFor patients who indicated "no change" in the SSQ, the mean change in scores in the corresponding QLQ-C30 domains was n...

read more

Citations
More filters
Journal ArticleDOI

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, +17 more
- 11 May 2011 - 
TL;DR: FOLFIRINOX was associated with a survival advantage and had increased toxicity as compared with gemcitabine, and is an option for the treatment of patients with metastatic pancreatic cancer and good performance status.
Journal ArticleDOI

Erlotinib in previously treated non-small-cell lung cancer.

Frances A. Shepherd, +18 more
- 14 Jul 2005 - 
TL;DR: Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Journal ArticleDOI

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Christos S. Karapetis, +15 more
- 23 Oct 2008 - 
TL;DR: Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ra did benefit fromcetuxIMab.
Journal ArticleDOI

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris, +22 more
- 08 Oct 2016 - 
TL;DR: Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy.
Journal ArticleDOI

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Lecia V. Sequist, +19 more
- 20 Sep 2013 - 
TL;DR: The LUX-Lung 3 study as mentioned in this paper investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epIDERmal growth factors receptor 2 (HER2/ERbB2), and ErbbB4 and has wide-spectrum preclinical activity against EGFR mutations.
References
More filters
Journal ArticleDOI

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

Neil K. Aaronson, +18 more
- 03 Mar 1993 - 
TL;DR: The reliability and validity of the EORTC QLQ-C30 questionnaire were highly consistent across the three language-cultural groups studied: patients from English-speaking countries, Northern Europe, and Southern Europe.
Journal ArticleDOI

Measurement of health status: Ascertaining the minimal clinically important difference

Roman Jaeschke, +2 more
- 01 Dec 1989 - 
TL;DR: An approach to elucidating the significance of changes in score in quality of life instruments by comparing them to global ratings of change is developed, and a plausible range within which the minimal clinically important difference (MCID) falls is established.

EORTC QLQ-C30 Scoring Manual

Peter Fayers, +8 more
Journal ArticleDOI

Determining a minimal important change in a disease-specific quality of life questionnaire

Elizabeth F. Juniper, +3 more
- 01 Jan 1994 - 
TL;DR: The observation that the minimal important difference is consistent across domains and for both improvement and deterioration will facilitate interpretation of results of studies examining quality of life.
Journal ArticleDOI

The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30

Madeleine King
- 01 Dec 1996 - 
TL;DR: An approach to developing clinically-based interpretations for QOL outcomes, using the QLQ-C30 as an example, provides a sense of the relative sizes of means and of differences, and of the types of clinical groups which give rise to them, thereby providing clinically- based benchmarks by which to interpret QLZC30 results.
Related Papers (5)

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

Neil K. Aaronson, +18 more
- 03 Mar 1993 - 

EORTC QLQ-C30 Scoring Manual

Peter Fayers, +8 more

Measurement of health status: Ascertaining the minimal clinically important difference

Roman Jaeschke, +2 more
- 01 Dec 1989 - 

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

David Cella, +9 more
- 01 Mar 1993 - 

The Hospital Anxiety and Depression Scale.

A. S. Zigmond, +1 more
- 01 Jun 1983 -